INVO · Invo Bioscience, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.43M | $1.84M | $1.64M | - | $1.43M | $1.84M | $1.58M | - | $974.9K | $315.9K |
| Cost of Revenue | - | - | $1.06M | - | $988.5K | $235.7K | $850.2K | - | - | - |
| Gross Profit | - | - | $577.5K | - | $444.7K | $1.60M | $726.1K | - | - | - |
| R&D | - | - | $265.7K | - | - | - | $4.9K | - | $2.7K | $83.8K |
| SG&A | $2.13M | $2.19M | $2.55M | - | $1.51M | $2.65M | $1.44M | - | $1.26M | $2.04M |
| Total Operating Expenses | $3.39M | $4.85M | $18.74M | - | $1.86M | $2.38M | $2.52M | - | $1.86M | $2.38M |
| D&A | $136.7K | $169.7K | $234.5K | - | $230.5K | $230.3K | $227.0K | - | $20.5K | $19.7K |
| Operating Income | ($1.64M) | ($2.99M) | ($17.11M) | - | ($1.30M) | ($1.90M) | ($946.4K) | - | ($886.3K) | ($2.07M) |
| Interest Expense | $145.8K | $221.3K | ($311.3K) | - | $352.1K | $175.2K | $181.3K | - | $352.1K | $175.2K |
| Income Tax | - | - | - | - | $29.3K | - | $1.8K | - | $1.9K | $2.9K |
| Net Income | ($2.64M) | ($5.28M) | ($17.40M) | - | ($1.63M) | ($2.25M) | ($1.60M) | - | ($1.25M) | ($2.24M) |
| EPS - Basic | ($0.77) | ($13.30) | ($12.53) | - | ($0.42) | ($0.62) | ($0.42) | - | ($0.70) | ($3.06) |
| EPS - Diluted | ($0.77) | ($13.30) | ($12.53) | - | ($0.42) | ($0.62) | ($0.42) | - | ($0.70) | ($3.06) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $355.9K | $549.2K | $840.4K | $741.4K | $471.6K | $942.9K | $475.1K | $232.4K | $1.06M | $112.5K |
| Accounts Receivable | $274.2K | $242.3K | $173.6K | $174.9K | $257.1K | $257.2K | $176.9K | $140.6K | $116.8K | $74.9K |
| Inventory | $191.8K | $212.6K | $216.5K | $219.8K | $241.5K | $250.1K | $266.5K | $264.5K | $254.2K | $280.0K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $1.14M | $1.40M | $1.57M | $1.32M | $1.96M | $2.40M | $1.72M | $1.26M | $1.79M | $842.1K |
| Total Assets | $18.83M | $19.32M | $31.74M | $46.45M | $17.02M | $18.03M | $18.32M | $20.89M | $19.48M | $6.64M |
| Current Liabilities | $9.24M | $12.46M | $18.72M | $17.93M | $8.66M | $7.99M | $8.96M | $8.22M | $4.88M | $4.47M |
| Long-term Debt | $951.7K | $1.13M | - | - | - | - | - | - | - | - |
| Total Liabilities | $12.98M | $16.69M | $24.43M | $26.24M | $17.04M | $16.67M | $18.31M | $19.99M | $19.10M | $8.34M |
| Stockholders' Equity | $5.85M | $2.63M | $3.34M | $12.75M | ($23.3K) | $1.36M | $10.2K | $892.8K | $372.8K | ($1.71M) |
| Retained Earnings | ($93.09M) | ($90.20M) | ($84.87M) | ($67.16M) | ($63.54M) | ($61.91M) | ($59.41M) | ($57.82M) | ($55.82M) | ($54.57M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.55M) | - | - | - | ($260.6K) | - | - | - |
| Investing Cash Flow | - | - | ($14.7K) | - | - | - | ($24.1K) | - | - | - |
| Financing Cash Flow | - | - | $3.66M | - | - | - | $527.4K | - | - | - |
| CapEx | - | - | $14.7K | - | - | - | $49.7K | - | - | - |
| Free Cash Flow | - | - | ($3.56M) | - | - | - | ($310.3K) | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | 35.2% | - | 31.0% | 87.2% | 46.1% | - | - | - |
| Operating margin | -114.1% | -162.8% | -1042.1% | - | -90.7% | -103.6% | -60.0% | - | -90.9% | -654.0% |
| EBITDA margin | -104.6% | -153.6% | -1027.8% | - | -74.7% | -91.1% | -45.6% | - | -88.8% | -647.8% |
| Net margin | -184.5% | -287.8% | -1060.1% | - | -113.8% | -122.2% | -101.3% | - | -128.1% | -709.2% |
| Free cash flow margin | - | - | -216.9% | - | - | - | -19.7% | - | - | - |
| FCF / Net income | - | - | 0.20 | - | - | - | 0.19 | - | - | - |
| R&D / Revenue | - | - | 16.2% | - | - | - | 0.3% | - | 0.3% | 26.5% |
| SG&A / Revenue | 148.5% | 119.4% | 155.6% | - | 105.7% | 144.2% | 91.4% | - | 128.9% | 646.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.0% | -27.4% | -54.8% | - | -9.6% | -12.5% | -8.7% | - | -6.4% | -33.7% |
| Return on equity | -45.2% | -200.8% | -521.8% | - | 6993.7% | -164.7% | -15721.4% | - | -334.9% | 131.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.12 | 0.11 | 0.08 | 0.07 | 0.23 | 0.30 | 0.19 | 0.15 | 0.37 | 0.19 |
| Quick ratio | 0.10 | 0.10 | 0.07 | 0.06 | 0.20 | 0.27 | 0.16 | 0.12 | 0.31 | 0.13 |
| Cash ratio | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.12 | 0.05 | 0.03 | 0.22 | 0.03 |
| Leverage | ||||||||||
| Debt / Equity | 0.16 | 0.43 | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.05 | 0.06 | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -11.2x | -13.5x | 55.0x | - | -3.7x | -10.9x | -5.2x | - | -2.5x | -11.8x |
| Equity multiplier | 3.22 | 7.34 | 9.52 | 3.64 | -729.95 | 13.22 | 1803.82 | 23.40 | 52.24 | -3.89 |
| Liabilities / Assets | 0.69 | 0.86 | 0.77 | 0.57 | 1.00 | 0.92 | 1.00 | 0.96 | 0.98 | 1.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.08 | 0.10 | 0.05 | - | 0.08 | 0.10 | 0.09 | - | 0.05 | 0.05 |
| Inventory turnover | - | - | 4.92 | - | 4.09 | 0.94 | 3.19 | - | - | - |
| Days sales outstanding | 70d | 48d | 39d | - | 65d | 51d | 41d | - | 44d | 87d |
| Days inventory outstanding | - | - | 74d | - | 89d | 387d | 114d | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.0% | 0.0% | 4.1% | - | 47.0% | 481.4% | 352.9% | - | 314.3% | 116.2% |
| Revenue CAGR (3y) | 82.6% | 132.5% | 116.1% | - | 62.2% | 106.5% | 82.7% | - | 42.6% | 8.7% |
| Revenue CAGR (5y) | 33.7% | 49.5% | 44.7% | - | 36.4% | 22.8% | 52.8% | - | 50.8% | 23.4% |
| Gross profit growth (YoY) | - | - | -20.5% | - | - | - | 163.6% | - | - | - |
| Operating income growth (YoY) | -25.8% | -57.1% | -1707.7% | - | -46.7% | 7.9% | 59.0% | - | 64.9% | 23.0% |
| Net income growth (YoY) | -62.2% | -135.4% | -990.1% | - | -30.6% | -0.2% | 37.4% | - | 51.0% | 20.0% |
| EPS growth (YoY) | -83.3% | -2045.2% | -2883.3% | - | 40.0% | 79.7% | -110.0% | - | -233.3% | -1230.4% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -1047.5% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 93.0% | 32744.6% | 1327.8% | - | - | -88.5% | - | -71.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$6.87M totalFertility Clinic Services$6.72M · 97.9%
Invocell Device$147.2K · 2.1%
Product / service
$13.59M totalClinic Revenue$6.72M · 49.5%
Revenue From External Customers$6.72M · 49.5%
Product$120.2K · 0.9%
Inter Segment Revenue$27.0K · 0.2%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing INVO Bioscience against the 5 most active filers in the same SIC group.